Back to School: How biopharma can reboot drug development. Access exclusive analysis here

PDLI waiting to find out why it lost

Besides its core focus on developing humanized antibody therapeutics for a variety of indications, Protein Design Labs Inc. has enjoyed a brisk business licensing its technology to companies interested in humanizing their own antibodies,

Read the full 342 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers